The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Cited by (1,044)

Items 401–500 of 1,044

1. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
   Butler, Javed, Packer, Milton, Filippatos, Gerasimos, Ferreira, Joao Pedro, Zeller, Cordula, Schnee, Janet, Brueckmann, Martina, Pocock, Stuart J, Zannad, Faiez, Anker, Stefan D · 2022 · European Heart Journal
2. Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients
   Scott David Solomon, Duolao Wang, Peter V. Finn, Hicham Skali, Leonardo Antônio Mamede Zornoff, John J.V. McMurray, Karl B Swedberg, Salim Yusuf, Christopher Bull Granger, Eric L. Michelson et al. · 2004 · Circulation
3. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
   Lisa C. Costello‐Boerrigter, William B. Smith, Guido Boerrigter, John Ouyang, Christopher A. Zimmer, Cesare Orlandi, John C. Jr Burnett · 2005 · American Journal of Physiology-Renal Physiology
4. Spironolactone in Addition to ACE Inhibition to Reduce Proteinuria in Patients with Chronic Renal Disease
   Anastasia Chrysostomou, Gavin J. Becker · 2001 · New England Journal of Medicine
5. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity
   Packer, Milton · 2018 · Circulation
6. Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies
   Judith L. Turgeon, Molly C. Carr, Pauline M. Maki, Michael E. Mendelsohn, Phyllis M. Wise · 2006 · Endocrine Reviews
7. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
   Peter Kolkhof, Lars Bärfacker · 2017 · Journal of Endocrinology
8. Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Conn’s Registry
   E. Born-Frontsberg, Martín Reincke, L. C. Rump, Stefanie Hahner, Sven Diederich, Reinhard L. Lorenz, Bruno Allolio, Jochen Seufert, Caroline Schirpenbach, Felix Beuschlein et al. · 2009 · The Journal of Clinical Endocrinology & Metabolism
9. Use of Aldosterone Antagonists in Heart Failure
   Nancy M. Albert · 2009 · JAMA
10. Quantification of Diffuse Myocardial Fibrosis and Its Association With Myocardial Dysfunction in Congenital Heart Disease
    Craig S. Broberg, Sumeet S. Chugh, Catherine Conklin, David J. Sahn, Michael Jerosch‐Herold · 2010 · Circulation Cardiovascular Imaging
11. Aldosterone, Inflammation, Immune System, and Hypertension
    Nathanne Santos Ferreira, Rita C. Tostes, Pierre Paradis, Ernesto L. Schiffrin · 2020 · American Journal of Hypertension
12. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review
    Bomback, Andrew S., Kshirsagar, Abhijit V., Amamoo, M. Ahinee, Klemmer, Philip J. · 2008 · American Journal of Kidney Diseases
13. The Prevention of Hospital Readmissions in Heart Failure
    Boback Ziaeian, Gregg C. Fonarow · 2015 · Progress in Cardiovascular Diseases
14. The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy
    Stella Styliani Daskalopoulou, Nadia A. Khan, Robert Ross Quinn, Marcel Ruzicka, Donald W. McKay, Daniel G. Hackam, Simon W. Rabkin, Doreen M. Rabi, Richard E. Gilbert, Raj S. Padwal et al. · 2012 · Canadian Journal of Cardiology
15. Transgenic Model of Aldosterone-Driven Cardiac Hypertrophy and Heart Failure
    Wenning Qin, Amy E. Rudolph, Brian R. Bond, Ricardo Rocha, Eric A.G. Blomme, Joseph J. Goellner, John W. Funder, Ellen Garwitz McMahon · 2003 · Circulation Research
16. Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
    Jonatan Barrera‐Chimal, Ixchel Lima‐Posada, George L. Bakris, Frédéric Jaisser · 2021 · Nature Reviews Nephrology
17. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials
    Faris, R, Flather, M, Purcell, H, Henein, M, Poole-Wilson, P, Coats, A · 2002 · International Journal of Cardiology
18. Glucocorticoids Activate Cardiac Mineralocorticoid Receptors During Experimental Myocardial Infarction
    Anastasia Susie Mihailidou, Thi Yen Loan Le, Mahidi Mardini, John W. Funder · 2009 · Hypertension
19. Treatment of Hypertension in Patients With Coronary Artery Disease
    Clive Rosendorff, Daniel T. Lackland, Matthew Allison, Wilbert S. Aronow, Henry R. Black, Roger Scott Blumenthal, Christopher Paul Cannon, James A. de Lemos, W.J. Elliott, Laura Findeiss et al. · 2015 · Circulation
20. The Pathophysiology of Aldosterone in the Cardiovascular System
    RICARDO ROCHA, John W. Funder · 2002 · Annals of the New York Academy of Sciences
21. Protective Effects of Spironolactone Against Anthracycline-Induced Cardiomyopathy
    Mahmut Akpek, İbrahіm Özdoğru, Ömer Şahin, Mevlüde İnanç, Ali Doğan, Cevat Yazıcı, Velı Berk, Halıt Karaca, Nihat Kalay, Abdurrahman Oğuzhan et al. · 2014 · European Journal of Heart Failure
22. Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases
    Johann K Bauersachs, Frédéric Jaisser, Robert D. Toto · 2014 · Hypertension
23. Induction of Cardiac Fibrosis by Aldosterone
    Paul J Lijnen, Victor Petrov · 2000 · Journal of Molecular and Cellular Cardiology
24. Review of aldosterone- and angiotensin II-induced target organ damage and prevention
    Allan D. Struthers · 2004 · Cardiovascular Research
25. Hypertension and Heart Failure
    Jeremy A. Slivnick, Brent C. Lampert · 2019 · Heart Failure Clinics
26. Prevalence and Physiological Predictors of Sleep Apnea in Patients With Heart Failure and Systolic Dysfunction
    Dai Yumino, Hanqiao Wang, John S. Floras, Gary E. Newton, Susanna S Mak, Pimon Ruttanaumpawan, John D. Parker, Thomas Douglas Bradley · 2009 · Journal of Cardiac Failure
27. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases
    Hans Schepkens, Raymond C. Vanholder, Jean-Marie Billiouw, Norbert Lameire · 2001 · The American Journal of Medicine
28. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial
    Subha V. Raman, Kan N. Hor, Wojciech M. Mazur, Nancy J. Halnon, John T. Kissel, Xin He, Tam Tran, Suzanne Smart, Beth McCarthy, Michael D. Taylor et al. · 2014 · The Lancet Neurology
29. Decompensated heart failure: symptoms, patterns of onset, and contributing factors
    Gordon D. Schiff, Sharon Fung, Theodore Speroff, Robert Mcnutt · 2003 · The American Journal of Medicine
30. Aldosterone and Vascular Inflammation
    Nancy Jeanne Brown · 2008 · Hypertension
31. 2024 Clinical practice guidelines for Chronic heart failure
    Albert S. Galyavich, Sergey N. Tereshchenko, T. M. Uskach, Fail T. Ageev, D. M. Aronov, G. P. Arutyunov, Yu. L. Begrambekova, Yu. N. Belenkov, Sergey Anatol'evich Boytsov, Marina Gennad'evna Bubnova et al. · 2024 · Russian Journal of Cardiology
32. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women
    Flavia Franconi, Ilaria Campesi · 2013 · British Journal of Pharmacology
33. Advances In The Prevention And Treatment Of Cardiovascular Disease
    Myron L. Weisfeldt, Susan J. Zieman · 2007 · Health Affairs
34. HEART FAILURE SOCIETY OF AMERICA (HFSA) PRACTICE GUIDELINES
    HEART FAILURE SOCIETY OF AMERICA · 2000 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
35. Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function
    Romain Eschalier, John J.V. McMurray, Karl B Swedberg, Dirk Jan van Veldhuisen, Henry Krum, Stuart Pocock, Harry H. Shi, John Vincent, Patrick Rossignol, Faiez M. Zannad et al. · 2013 · Journal of the American College of Cardiology
36. Aldosterone antagonists for preventing the progression of chronic kidney disease
    Davide Bolignano, Suetonia C. Palmer, Sankar Dass Navaneethan, Giovanni FM Strippoli · 2014 · Cochrane Database of Systematic Reviews
37. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction
    Michael M. Givertz, Lynne Warner Stevenson, Maria Rosa Costanzo, Robert C. Bourge, Jordan G. Bauman, Greg Ginn, William T. Abraham · 2017 · Journal of the American College of Cardiology
38. Combination Therapy With an Angiotensin Receptor Blocker and an ACE Inhibitor in Proteinuric Renal Disease: A Systematic Review of the Efficacy and Safety Data
    Martin MacKinnon, Sabin Shurraw, Ayub Akbari, Greg A. Knoll, James Jaffey, Heather D. Clark · 2006 · American Journal of Kidney Diseases
39. How Dangerous Is Hyperkalemia?
    John R. Montford, Stuart L. Linas · 2017 · Journal of the American Society of Nephrology
40. C-Reactive Protein as a Predictor of Improvement and Readmission in Heart Failure
    José Luis Alonso-Martínez, B. Llorente‐Diez, M. Echegaray Agara, Fernando Olaz Preciado, Miren Aránzazu Urbieta-Echezarreta, Carmen González Arencibia · 2002 · European Journal of Heart Failure
41. Characteristics, Outcomes, and Predictors of Mortality at 3 Months and 1 Year in Patients Hospitalized for Acute Heart Failure
    Veli‐Pekka Harjola, Ferenc Folláth, Markku S. Nieminen, Dirk L. Brutsaert, Kenneth Dickstein, Helmut Drexler, Matthias Hochadel, Michel Komajda N, Jose Luis Lopez-Sendon, Piotr P. Ponikowski et al. · 2010 · European Journal of Heart Failure
42. The Renin-Angiotensin-Aldosterone System: Cardiorenal Effects and Implications for Renal and Cardiovascular Disease States
    Ursula C. Brewster, Mark Anthony Perazella, John Francis Setaro · 2003 · The American Journal of the Medical Sciences
43. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone
    Beixin Julie He, Mei-ling A. Joiner, Madhu V. Singh, Elizabeth D. Luczak, Paari S. Dominic, Olha M. Koval, William J. Kutschke, Chantal Allamargot, Jinying Yang, Xiaoqun Guan et al. · 2011 · Nature Medicine
44. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis
    Burnett, Heather, Earley, Amy, Voors, Adriaan A., Senni, Michele, McMurray, John J.V., Deschaseaux, Celine, Cope, Shannon · 2017 · Circulation Heart Failure
45. Beneficial impact of spironolactone in diabetic nephropathy
    Katrine Jordan Schjoedt, Kasper Rossing, Tina R. Juhl, Frans Boomsma, Peter R Rossing, Lise Tarnow, Hans‐Henrik Parving · 2005 · Kidney International
46. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial
    Javed Butler, Stefan D. Anker, Lars H. Lund, Andrew J.S. Coats, Gerasimos S Filippatos, Tariq Jamal Siddiqi, Tim Friede, Vincent Fabien, Mikhail Kosiborod, Marco Metra et al. · 2022 · European Heart Journal
47. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary
    pre-diabetes Task Force on diabetes · 2014 · Diabetes and Vascular Disease Research
48. Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)
    Bertram Pitt, George L. Bakris, Luis Miguel Ruilope, Lorenzo A. DiCarlo, Robin Mukherjee · 2008 · Circulation
49. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
    John G.F. Cleland, Claude Daubert, Erland Erdmann · 2005 · ACC Current Journal Review
50. Aldosterone as a Mediator of Cardiovascular Damage
    Fabrizio Buffolo, Martina Tetti, Paolo Mulatero, Silvia Monticone · 2022 · Hypertension
51. Central Sleep Apnea and Cheyne-Stokes Respiration
    Dai Yumino, Thomas Douglas Bradley · 2008 · Proceedings of the American Thoracic Society
52. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities
    Jason J Gajarsa, Robert Alan Kloner · 2010 · Heart Failure Reviews
53. Medication prescribing in frail older people
    Ruth Eleanor Hubbard, M. Sinead O'Mahony, Kenneth W. Woodhouse · 2012 · European Journal of Clinical Pharmacology
54. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice
    Ayumu Hirata, Norikazu Maeda, Aki Hiuge, Toshiyuki Hibuse, Koichi Fujita, Takuya Okada, Shinji Kihara, Tohru Funahashi, Iichiro Shimomura · 2009 · Cardiovascular Research
55. Chronic Heart Failure: Contemporary Diagnosis and Management
    Gautam V. Ramani, Patricia A. Uber, Mandeep R. Mehra · 2010 · Mayo Clinic Proceedings
56. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study
    J. Malcolm O. Arnold, Salim Yusuf, James B. Young, James Mathew, David E. Johnstone, Álvaro Avezum, Eva Lonn, Janice Pogue, Jackie Bosch · 2003 · Circulation
57. Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy
    Natalia Tsybouleva, Lianfeng Zhang, Suetnee Chen, Rajnikant T. Patel, Silvia Lutucuta, Shintaro Nemoto, Gilberto DeFreitas, Mark L. Entman, Blase Anthony Carabello, Robert Roberts et al. · 2004 · Circulation
58. Excess ldosterone Is Associated With Alterations of Myocardial Texture in Primary Aldosteronism
    Gian Paolo Rossi, Vitantonio Di Bello, Chiara Ganzaroli, Alfredo Sacchetto, Maurizio Cesari, ALESSIO BERTINI, Davide Giorgi, Roldano Scognamiglio, Mario Mariani, Achille Cesare Pessina · 2002 · Hypertension
59. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
    Iris E. Beldhuis, Carolyn S.P. Lam, Jeffrey M. Testani, Adriaan A. Voors, Harriette G.C. Van Spall, Jozine M. ter Maaten, Kevin Damman · 2022 · Circulation
60. Mineralocorticoid Receptors: Distribution and Activation
    John W. Funder · 2005 · Heart Failure Reviews
61. Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population‐based cohort study
    John M. Davis, Hilal Maradit Kremers, Cynthia S. Crowson, Paulo Nicola, Karla V. Ballman, Terry M. Therneau, Veronique Lee Roger, Sherine E. Gabriel · 2007 · Arthritis & Rheumatism
62. Drug dosing adjustments in patients with chronic kidney disease.
    Myrna Y. Munar, Harleen Singh · 2007 · PubMed
63. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
    Milton Packer · 2017 · Circulation
64. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality
    Gregg C. Fonarow, Clyde W. Yancy, Adrian F. Hernandez, Eric David Peterson, John A. Spertus, Paul A. Heidenreich · 2011 · American Heart Journal
65. Mode of Death in Advanced Heart Failure
    Peter E. Carson, Inder S. Anand, Christopher J. O’Connor, Brian E. Jaski, Jonathan S. Steinberg, Amy Lwin, JoAnn Lindenfeld, Jalil Ghali, Jodi H. Barnet, Arthur Michael Feldman et al. · 2005 · Journal of the American College of Cardiology
66. Heart failure with preserved ejection fraction
    James D. Gladden, Wolfgang Albrecht Linke, Margaret M. Redfield · 2014 · Pflügers Archiv - European Journal of Physiology
67. Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial
    Calhoun, David A., White, William B., Krum, Henry, Guo, Weinong, Bermann, Georgina, Trapani, Angelo, Lefkowitz, Martin P., Ménard, Joël · 2011 · Circulation
68. Factors Associated with Underuse of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction: An Analysis of 11 215 Patients from the Swedish Heart Failure Registry
    Gianluigi Savarese, Juan Jesús Carrero, Bertram Pitt, Stefan D. Anker, Giuseppe M.C. Rosano, Ulf Dahlström, Lars H. Lund · 2018 · European Journal of Heart Failure
69. Plasma aldosterone is independently associated with the metabolic syndrome
    Bochud, Murielle, Nussberger, Jürg, Bovet, Pascal, Maillard, Marc R., Elston, Robert C., Paccaud, Fred, Shamlaye, Conrad, Burnier, Michel · 2006 · Hypertension
70. How Evidence-Based Are the Recommendations in Evidence-Based Guidelines?
    Finlay Aleck McAlister, Sean van Diepen, Raj S. Padwal, Jeffrey A. Johnson, Sumit R. Majumdar · 2007 · PLoS Medicine
71. Cardiovascular Autonomic Neuropathy Due to Diabetes Mellitus: Clinical Manifestations, Consequences, and Treatment
    Raelene E. Maser, M. James Lenhard · 2005 · The Journal of Clinical Endocrinology & Metabolism
72. Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction
    Daniela Fraccarollo, Stefan Berger, Paolo Galuppo, Susanne Kneitz, Lutz Hein, Günther Schütz, Stefan Frantz, Georg Ertl, Johann K Bauersachs · 2011 · Circulation
73. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children
    David N. Rosenthal, Maryanne Chrisant, Erik Edens, Lynn Mahony, Charles E. Canter, Steven D. Colan, Anne Marie Dubin, J.M. Lamour, Robert D. Ross, Robert E. Shaddy et al. · 2004 · The Journal of Heart and Lung Transplantation
74. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril
    Akshay Suvas Desai, Orly Vardeny, Brian Lee Claggett, John J.V. McMurray, Milton Packer, Karl B Swedberg, Jean Lucien Rouleau, Michael R. Zile, Martin P. Lefkowitz, Victor Chengwei Shi et al. · 2016 · JAMA Cardiology
75. Ventricular–Vascular Interaction in Heart Failure
    Barry A. Borlaug, David A. Kass · 2011 · Cardiology Clinics
76. JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
    Takeshi Kitai, Shun Kohsaka, Takao Kato, Eri Toda Kato, Kimi Sato, KANAKO TERAMOTO, Hidenori Yaku, Eiichi Akiyama, Masahiko Ando, Chisato Izumi et al. · 2025 · Circulation Journal
77. The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative Stress
    Camila Margarita Manrique, Guido Lastra, Michael Gardner, James R. Sowers · 2009 · Medical Clinics of North America
78. Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
    Yoshihiro Matsumoto, Yasuo Mori, Shinji Kageyama, Kazuo Arihara, Toshikazu Sugiyama, Hiromichi Ohmura, Toru Yakushigawa, Hatsumi Sugiyama, Yasushi Shimada, Y Nojima et al. · 2013 · Journal of the American College of Cardiology
79. Aldosterone and end-organ damage
    Annis M. Marney, Nancy Jeanne Brown · 2007 · Clinical Science
80. Trends in hospitalization for heart failure in Scotland, 1990–1996. An epidemic that has reached its peak?
    Simon Stewart · 2001 · European Heart Journal
81. Pathophysiology of chronic heart failure
    Gary S Francis · 2001 · The American Journal of Medicine
82. Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats
    Kohzo Nagata, Koji Obata, Jinglan Xu, Sahoko Ichihara, Akiko Noda, Hirotaka Kimata, Tomoko Kato, Hideo Izawa, Toyoaki Murohara, Mitsuhiro Yokota · 2006 · Hypertension
83. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients
    John M. Flack, Suzanne Oparil, John Howard Pratt, Barbara Roniker, Susan M. Garthwaite, Jay H. Kleiman, Yonghong Yang, Scott L. Krause, Diane L. Workman, Elijah Saunders · 2003 · Journal of the American College of Cardiology
84. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines
    Biykem Bozkurt, Ildiko Agoston, Anne A. Knowlton · 2003 · Journal of the American College of Cardiology
85. The hypertension of Cushing's syndrome
    Andrea Maria Isidori, Chiara Graziadio, Rosa Maria Paragliola, Alessia Cozzolino, Alberto Giacinto Ambrogio, Annamaria Colao, Salvatore Maria Corsello, Rosario Pivonello · 2014 · Journal of Hypertension
86. Gender medicine: a task for the third millennium
    Giovannella Baggio, Alberto Corsini, Annarosa Floreani, Sandro Giannini, Vittorina Zagonel · 2013 · Clinical Chemistry and Laboratory Medicine (CCLM)
87. How to assess the external validity of therapeutic trials: a conceptual approach
    Dekkers, O M, Elm, E v., Algra, A, Romijn, J A, Vandenbroucke, J P · 2010 · International Journal of Epidemiology
88. Evaluation and Management of Breast Pain
    Robin L. Smith, Sandhya Pruthi, Lorraine A. Fitzpatrick · 2004 · Mayo Clinic Proceedings
89. Sodium Nitroprusside for Advanced Low-Output Heart Failure
    Wilfried Müllens, Zuheir Abrahams, Gary S. Francis, Hadi N. Skouri, Randall C. Starling, James B. Young, David O. Taylor, W.H. Wilson Tang · 2008 · Journal of the American College of Cardiology
90. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure
    Mark T. Kearney, Keith A.A. Fox, Amanda Jane Lee, Robin John Prescott, Ajay M. Shah, Philip D. Batin, Wazir Baig, Stephen F. Lindsay, Timothy S. Callahan, William E. Shell et al. · 2002 · Journal of the American College of Cardiology
91. Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal Disease
    Nishank Jain, Suman Krishna Kotla, Bertis B. Little, Rick A. Weideman, Emmanouil S. Brilakis, Robert F. Reilly, Subhash Banerjee · 2012 · The American Journal of Cardiology
92. Aldosterone Potentiates Angiotensin II–Induced Signaling in Vascular Smooth Muscle Cells
    Mazak, Istvan, Fiebeler, Anette, Muller, Dominik N., Park, Joon-Keun, Shagdarsuren, Erdenechimeg, Lindschau, Carsten, Dechend, Ralf, Viedt, Christiane, Pilz, Bernhard, Haller, Hermann et al. · 2004 · Circulation
93. Effect of Vitamin D Supplementation on Blood Pressure in Blacks
    John P. Forman, Jamil B. Scott, Kimmie Ng, Bettina F. Drake, Elizabeth Gonzalez Suarez, Douglas L. Hayden, Gary G. Bennett, Paulette D. Chandler, Bruce W. Hollis, Karen M. Emmons et al. · 2013 · Hypertension
94. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations
    Richard F. Hobbs, R C Davis, A K Roalfe, R Hare, M K Davies, J E Kenkre · 2002 · BMJ
95. Long-Term Prognostic Impact of Therapeutic Strategies in Patients with Idiopathic Dilated Cardiomyopathy: Changing Mortality over the Last 30 Years
    Marco Merlo, Alberto Pivetta, Bruno Pinamonti, Davide Stolfo, Massimo Zecchin, Giulia Barbati, Andrea Di Lenarda, Gianfranco Sinagra · 2013 · European Journal of Heart Failure
96. Heart Failure with Preserved Ejection Fraction: Clinical Characteristics of 4133 Patients Enrolled in the I-PRESERVE Trial
    John J.V. McMurray, Peter E. Carson, Michel Komajda N, Robert Samuel McKelvie, Michael R. Zile, Agata Ptaszynska, Christoph Staiger, J. Mark Donovan, Barry M. Massie · 2008 · European Journal of Heart Failure
97. A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor
    Randy K. Bledsoe, Kevin P. Madauss, Jason A. Holt, Christopher J. Apolito, Millard H. Lambert, Kenneth H. Pearce, Thomas B. Stanley, Eugene L. Stewart, Ryan P. Trump, Timothy Mark Willson et al. · 2005 · Journal of Biological Chemistry
98. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)
    Subcommittee Guidelines · 2006 · Hypertension Research
99. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)
    Japanese Society of Hypertension · 2006 · Hypertension Research
100. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES)
     Richard F. Hobbs, Andrea K. Roalfe, Russell Davis, Michael K. Davies, Rachel Hare · 2007 · European Heart Journal